Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Munch-a-Biotech Today -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (319)	4/1/1999 4:19:00 PM
From: jeffbas	Read Replies (1) \| Respond to of 3158

A quick answer from memory, Rick. I believe that each ADR which is what we see trading is equal to 3 shares of the stock that IMUL holds. If my memory is right you have to divide the $1.20 by 3. Since you are more current on this than I, if this does not sound right let me know and I will look at it again.

To: scaram(o)uche who wrote (319)	4/1/1999 4:40:00 PM
From: Biomaven	Read Replies (2) \| Respond to of 3158

Rick, Company received 2,566,845 new Cantab Ordinary Shares of 2p each having a fair market value at the time of the sale of approximately $9,000,000, which Ordinary Shares are represented by 855,615 American Depositary Receipts ("ADRs"). The sale of this stock is subject to certain restrictions through April 2000. In addition, Cantab may pay ImmuLogic up to a maximum of $11,000,000 in milestone payments contingent upon successful development of the two programs to the end of Phase II clinical trials. The CNTBY ADRs have been trading at around $10, so this is potentially $8.5mm, or about $0.40 per IMUL share before any haircut. Some of the milestones are for Phase I, so are fairly likely. Peter